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Colon cancer is the second cause of death for neoplasm worldwide. In most cases it is 
diagnosed when still localized to the intestinal wall or in regional lymph nodes. 
Adjuvant therapy with 5-Fluorouracil (5FU) and folinic acid (FA), in combination 
with oxaliplatin (FOLFOX) are the standard options for patients with radically 
resected stage III disease. However, a proportion of patients will develop recurrence 
due to drug resistance and oxaliplatin-based chemotherapy is a regimen that may 
cause potentially disabling sensory neuropathy. Therefore there is an increase 
needing for a better selection of patients to be addressed to the most appropriate 
chemotherapeutic treatment, also in the adjuvant setting. 
Several proteins and genetic markers have been described in an attempt to refine 
prognostic information and predict the benefit derived from systemic treatment. In 
particular TS protein expression, MSI, p53 expression, BRAF and TP53 mutations, 
have been described in several reports in relation to 5FU treatment, whereas ERCC1 
polymorphism, ERCC1 expression and KRAS mutations, seem to be related to 
oxaliplatin efficacy in advanced colon cancer patients. 
At this purpose we enrolled 230 patients from Argentina and Switzerland who 
underwent surgical resection, followed by 6-months adjuvant treatment: 106 were 
treated with 5FU alone and 124 with FOLFOX. In all the cases we investigated the 
MSI status by fragment analysis, we analyzed BRAF, KRAS, TP53 mutations and 
ERCC1 codon 118 polymorphism by direct sequencing and we performed ERCC1 
expression analysis at protein and mRNA levels by immunohistochemistry and real-
time PCR, respectively. Finally, we correlated the molecular and 
immunohistochemical results with the clinical data. 
Above all, a little advantage in survival was observed for patients treated with 
FOLFOX regimen if compared to those treated with 5FU (51.3 and 41.6 months, 
respectively, for DFS; 55.4 and 49.3 months, respectively, for OS), although the 
difference was not statistically significant, probably due to the low number of 
analyzed cases. 
We found MSI in 12% of cases, BRAF mutations in 9% of cases, KRAS mutations in 
28% of cases and ERCC1 resulted over-expressed in 40% of cases detected by IHC 
and in 49% of cases detected by real-time PCR. These percentages, as well as the 
types of alterations, are in line with those published in the literature.  
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Concerning the correlations among markers, we observed a significant association 
between MSI and BRAF mutations (in agreement with the literature) and absence of 
association between KRAS mutations and ERCC1 expression (at odds with the 
hypothesis proposed in a recent preclinical study). 
When we matched the clinical data of the whole patients cohort with molecular 
alterations, we found a trend towards a better prognosis for patients with MSI than 
for those with a MSS status (p=0.17); we observed that KRAS mutations confer a 
worse prognosis to advanced colon cancer patients, borderline for the DFS (p=0.07) 
and statistically significant for the OS (p=0.004); finally we found a trend towards a 
better DFS (p=0.11) for patients showing low levels of ERCC1 mRNA expression. 
When we subdivided the patients on the basis of the received treatment (5FU versus 
oxaliplatin-based chemotherapy), we observed similar percentages of alterations of 
all the markers between the two groups. By correlating the molecular alterations with 
clinical data, we found a trend towards a better survival for MSI patients treated 5FU 
(p=0.16 and p=0.37 for DFS and OS, respectively), while for FOLFOX patients no 
clinical differences were found between MSI and MSS cases. 
As for KRAS mutations, in 5FU group we observed a statistical significant worse DFS 
(p=0.04) and a trend towards a worse OS (p=0.07) in KRAS mutated patients if 
compared to wild-type patients. In FOLFOX group, no statistical differences were 
identified between KRAS mutated and wild-type cases. Stratifying the population on 
the basis of KRAS mutational status, we noticed that in wild-type patients there was 
no difference in the clinical outcome in the two treatment modalities. On the 
contrary, in mutated cases a trend towards a better DFS (p=0.28) and OS (p=0.20) 
was observed in FOLFOX treated patients if compared to 5FU group. 
As regards ERCC1 expression, we found only a trend toward a better DFS (p=0.17) in 
patients characterized by low ERCC1 mRNA levels when treated with FOLFOX.  
As for the last markers, ERCC1 codon 118 polymorphism (AAT/AAC) and TP53 
mutations, we found percentages of alterations in line with the literature (for ERCC1 
polymorphism: TT genotype in 31% of cases, CC genotype in 21% of patients; for 
TP53: 44% of cases showed at least one mutation). The correlations between these 
two markers and the clinical outcome are now under evaluation. 
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In conclusion, looking at the whole cohort, we can confirm a better clinical outcome 
for adjuvant colon cancer patients treated with FOLFOX regimen with respect to 5FU 
treatment. MSI could be a useful tool indicating a better prognosis also for advanced 
colon cancer but its role in predicting 5FU or FOLFOX efficacy remains controversial. 
In addition, we propose to assess ERCC1 mRNA expression analysis before the 
administration of oxaliplatin-based chemotherapy, in order to early identify the 
patients who may benefit the most from this treatment. 
Finally, we suggest that KRAS mutational status could help clinicians in selecting the 
best chemotherapeutic treatment in the adjuvant setting: only KRAS mutant patients 
should be treated with a platinum-based chemotherapy, while patients whose 
tumour is KRAS wild-type can be treated with 5FU alone, thus preventing adverse 
side effect in a consistent number of cases. Our results, of course, deserve 
confirmations. 
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1.1 EPIDEMIOLOGY AND CANCEROGENESIS 
Colon cancer is the second cause of cancer-related death, accounting for over one 
million new cases per year worldwide (Parkin DM et al, 2005). There is no sex 
predominance in this tumour onset. Approximately 5% of colon cancers occur in 
patients with a chronic inflammatory disease, such as ulcerative colitis, or belonging 
to inherited families (Calvert PM et al, 2002). Thus, most colon cancers in Western 
countries are sporadic and are believed to be caused by environmental factors, such 
as red meat or alcohol consumption, high-fat diet, inadequate intake of fibres, 
obesity, sedentary lifestyle, diabetes mellitus and smoking (Cunningham D et al, 2010). 
The incidence of colon cancer is uncommon under the age of 50 years, where it 
occurs predominantly in patients with a family history. After 50 years, the risk to 
develop a colon cancer increases exponentially, doubling every decade (Rim SH et al, 
2009). Indeed two thirds of all colon cancers occurr in patients over the age of 65 
(Everhart JE et al, 2009). 
The disease originates from the epithelial cells lining the colon in the gastrointestinal 
tract (Figure 1).  
 
 
Figure 1: colon cancer (www.medicinenet.com) 
 
Half of all colon-rectal cancers takes place in the colon, with different distribution 
rates: 16% in caecum and ascending colon, 8% in transverse colon, 6% in descending 
colon and 20% in the sigmoid colon (Papadopoulos VN et al, 2004) (Figure 1).  
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Colon cancer does not arise de novo but rather is preceded by histological progression 
from a normal appearing mucosa at risk for colorectal neoplasia to neoplastic tubular 
and villous adenomas and then to carcinoma formation (Kronborg O et al, 1999) (Figure 2). 
This process takes about a decade or more and is accompanied by a large number of 
abnormalities in the genes of the colonic epithelium (Fearon ER and Vogelstein B, 1990). Two 
major types of colon cancer, characterized by different carcinogenic processes, have 
been identified. One, detected for about 15% of colon cancers, is characterized by 
normal karyotype, normal DNA index and genetic instability at microsatellite loci, 
and represents the so-called microsatellite instable (MSI) cancer (Samowitz WS et al, 2005). 
The second one, occurring in 80% or more of sporadic colon cancers, was firstly 
described by Vogelstein, who proposed a tight association between morphology 
changes and molecular alterations. This second type of colon carcinogenesis suggests 
that mutations in adenomatous polyposis coli gene (APC) represent the initial 
mutational events that determine hyperplastic proliferation and then early adenoma 
development. The stage of late adenoma is achieved with KRAS mutations, whilst 
the loss of tumour suppressor genes at chromosome 18q and mutations in TP53 gene 
lead to carcinoma in situ and then to the possibility to invade distant organs (the last 
process is named metastatization) (Fodde R et al, 2001) (Figure 2).  
Metastatic disease is present in approximately 20% of cases at the time of first colon 
cancer diagnosis (synchronous metastasis) and in another 30% appears later 
(metachronous metastasis). The common sites of metastasis are represented by liver 
(80% of cases), peritoneum and lung (Venook AP et al, 2004). 
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Figure 2: colon cancer formation according to Vogelstein model (www.medicinenet.com). 
 
The two molecular pathways proposed for sporadic cases, are also shared by patients 
affected by two hereditary syndromes: 
1. Hereditary non-polyposis colon cancer (HNPCC), caused by germline mutations in 
mismatch repair genes, which lead to MSI; 
2. Familial adenomatous polyposis (FAP), characterized by germline mutations in 
APC gene (Benson B, 2007). 
 
1.2 PROGNOSIS AND TREATMENT 
The most commonly used system for staging colon cancer is the TNM, which stands 
for Tumor, Nodes and Metastases. This staging system, edited by the American Joint 
Committee on Cancer, describes the size of a primary tumour (T), whether any 
lymph nodes contain cancer cells (N), and whether the cancer has spread to another 
part of the body (M). There are 4 stages of tumour in colon cancer (Figure 3): 
- T1: the tumour is only in the inner layer of the bowel; 
- T2: the tumour has grown into the muscle layer of the bowel wall; 
- T3: the tumour has grown into the outer lining of the bowel wall; 
- T4: the tumour has grown through the outer lining of the bowel wall. It 
may have grown into another part of the bowel, or into other nearby 
organs or structures, or it may have broken through the membrane 
covering the outside of the bowel (the peritoneum).    
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Figure 3: T stages of bowel cancer (www.cancerresearchuk.org). 
 
There are 3 possible stages describing the invasion of tumoral cells in lymph nodes, 
the presence of neoplastic cells or the number of involved lymph nodes: 
- N0: there are no lymph nodes containing cancer cells; 
- N1: 1 to 3 lymph nodes have tumoral cells; 
- N2: there are cancer cells in 4 or more lymph nodes. 
In the case of unknown information concerning lymph nodes involvement, the 
tumour is classified as Nx. 
There are 2 stages of cancer spread (metastasis): 
- M0: the cancer has not spread to other organs; 
- M1: the tumour has acquired the capability to invade distant organs. 
Mx means it is not known if distant organs are involved. 
Finally, there are 5 main stages to group colon cancer on the basis of TNM system: 
- Stage 1 identifies the cancer localized in the inner layer or in the muscle 
wall; 
- Stage 2 indicates that the cancer has grown up into the outer layer, 
covering the bowel wall and tissue or organs next to the bowel; 
- Stage 3 identifies the involvement of lymph nodes; 
- Stage 4 indicates the presence of distant metastases. 
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Colon cancer is characterized by a significant recurrence rate for which the depth of 
tumour penetration within the intestinal wall and the presence of involved lymph 
nodes are major prognostic factors (AJCC, 2009). The TNM classification serves as a 
benchmark for predicting the likelihood of 5-years survival as well as for choosing 
the best therapeutic option (Wolpin BM et al, 2007). In most cases, colon cancer is 
diagnosed when still confined in the intestinal wall or in regional lymph nodes. 
Surgery resection is the only curative therapy available for a localised disease; 
despite of this, approximately 50% of patients die within 5 years from the time of 
diagnosis and 80% of these will have a detectable recurrence within 2 years. Patients 
with non-resectable or disseminated disease have a very poor prognosis, with a 
median survival rate of few months.  
Generally, stage I and II tumors are curable by surgical resection alone, and up to 
70% of cases exhibiting a stage III disease are curable by surgery combined with 
adjuvant chemotherapy. Recent advances in chemotherapy have improved survival, 
but stage IV disease is usually incurable (Markowitz SD and Bertagnolli MM, 2009).  
Adjuvant chemotherapy for stage III disease mainly includes the use of 5-fluorouracil 
(5FU) or the more active oral fluoropyrimidine, capecitabine, which has reduced the 
risk of death by 30%. 5FU can be administered alone or in combination with 
oxaliplatin (FOLFOX), which improved the 3-years disease-free survival (DFS) 
(Midgley R and Kerr DJ, 2005). 
 
1.3 5-FLUOROURACIL AND OXALIPLATIN 
The gold standard chemotherapeutic agents for advanced colon cancer treatment are 
5FU and oxaliplatin, two compounds able to increase cell death by interfering with 
cell functions (Andrè T et al, 2004). 
5FU is a pyrimidine analogue, belonging to the family of drugs called 
antimetabolites. It can be administrated also as capecitabine and then converted in 
5FU active form after ingestion. It acts in several ways and various mechanisms such 
as:  
- inhibition of thymidylate synthase (TS) by 5-fluoro-20-deoxyuridine-50-
monophosphate (FdUMP), 
- incorporation of 5-fluorouridine-50-triphosphate (FUTP) into RNA, 
  Introduction   
  9  
-  incorporation of 5-fluoro-20-deoxyuridine-50-triphosphate (FdUTP) into 
DNA, 
inducing cell cycle arrest and apoptosis (Noordhuis P et al, 2004). 
TS inhibition seems to be the main mechanism of 5FU antitumor activity. 
Interrupting the action of this enzyme, in fact, blocks synthesis of the pyrimidine 
thymidine, which is a nucleoside required for DNA replication. The administration 
of 5FU causes a scarcity in thymidine monophosphate (dTMP) levels, produced by 
deoxyuridine monophosphate (dUMP) methylation due to TS action; so as a 
consequence rapidly dividing cancerous cells undergo death (Longley DB et al, 2003) 
(Figure 4). 
 
 
Figure 4: 5-FU mechanism of action (Nature Reviews Cancer, 2003). 
 
Oxaliplatin is a third generation 1,2–diaminocyclohexane platinum analogue with 
demonstrated preclinical and clinical activity (Scheeff ED et al, 1999; Vaisman A et al, 1999). In 
vitro studies have shown that 1,2-diaminocyclohexane-containing platinum drugs 
belong to a distinct group of cytotoxic compounds with different mechanisms of 
action and resistance than cisplatin and carboplatin (Giacchetti S et al, 2000; Sharp SY et al, 
2002). Oxaliplatin interferes with cellular activity by binding to DNA and forming 
DNA adducts leading to cross-links which disrupt the structure of the DNA 
molecule, preventing DNA replication and leading to cancer cells death (Seetharam R et 
al, 2009) (Figure 5). 
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Figure 5: Oxaliplatin mechanism of action (Bhushan S et al, 2009). 
 
1.4 ADJUVANT CHEMOTHERAPY AND ADVERSE EFFECTS 
In stage III colon cancer, postoperative adjuvant chemotherapy is the standard of 
care and it is associated with a statistically significant improvement in disease-free 
survival (DFS) (p=0.02) and overall survival (OS) (p=0.05) compared to surgery 
alone, enhancing the 3-year survival up to 71%. The National Surgical Adjuvant 
Breast and Bowel project (NSABP) trial, reported in 1988, was the first study to show 
such a survival advantage (Wolmark N et al, 1988).  
Before 2000, several new chemotherapeutic agents investigated for antitumor activity 
in the metastatic colorectal cancer setting were considered promising for the 
adjuvant treatment. The success in the late 1990s of irinotecan in US trials and of 
oxaliplatin in European trials in the treatment of mCRC, resulted in the initiation of 
clinical studies assessing the potential role of these agents in the adjuvant setting. 
Several phase III trials of oxaliplatin and irinotecan investigated potential 
improvement of patients outcomes when these agents were administered in 
combination with 5FU/leucovorin (LV) (de Gramont A, 2000; Saltz LB et al, 2000; Goldberg RM, 
2002; Andre T et al, 2004; Tournigand C et al, 2004) (Figure 6). In addition, capecitabine was 
introduced into the adjuvant setting to be investigated for its effect in comparison to 
bolus 5FU/LV (Twelves C et al, 2005). 
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Figure 6: Key clinical trials in the adjuvant colorectal carcinoma setting. 5-FU = 5-fluorouracil; CALGB 
= Cancer and Leukemia Group B; CPT-11 = irinotecan; CRC = colorectal carcinoma; DFS = disease-free 
survival; FOLFOX4 = 5-fluorouracil/leucovorin/oxaliplatin; GERCOR = Groupe d’Etude et de 
Recherche en Cancréologie Onco-Radiothérapic; IFL = irinotecan/fluorouracil/leucovorin; LV = 
leucovorin; LV5FU2 = leucovorin/5-fluorouracil; MOSAIC = Multicenter International Study of 
Oxaliplatin/5-FU/Leucovorin in the Adjuvant Treatment of Colon Cancer; NSABP = National 
Surgical Adjuvant Breast and Bowel Project; OS = overall survival; PETACC = Pan-European Trial in 
Adjuvant Colon Cancer; QUASAR = Quick and Simple and Reliable; UFT = uracil/tegafur; X-ACT = 
Xeloda in Adjuvant Colon Cancer Therapy (Marshall JL et al, 2007). 
 
Starting from these trials, drug regimens were improved substantially over the years 
and a 6-months combination of 5FU, folinic acid, and oxaliplatin (FOLFOX) became 
the reference treatment in 2004 showing a 0.76 hazard ratio (HR) (95% confidence 
interval [CI] 0.62-0.92) for relapse, favouring FOLFOX compared to fluorouracil plus 
folinic acid (André T et al, 2004). In a population of stage II-III colon cancer, FOLFOX is 
associated with a 3-year and 5-year survival rate of 72.2% and 78.5%, respectively. 
The current consensus is that adjuvant chemotherapy is indicated for stage III colon 
cancer treatment (Chau I et al, 2006). 
Unfortunately, this adjuvant setting is often associated with adverse effects: acute 
toxicity of the FOLFOX regimen has been well described as moderate to severe (André 
T et al, 2004). Common adverse effects linked to 5FU use include diarrhoea and 
heartburn. On the other hand, peripheral sensory neuropathy, in addition to 
myelosuppression, remains the most common adverse event associated with 
oxaliplatin, and represents the primary reason for treatment discontinuation. The 
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toxicity of oxaliplatin affects the peripheral nervous system in two distinct forms. 
Firstly, it is characterized by an acute reversible sensory neuropathy without 
persistent impairment of sensory functions. Secondly, it manifests dose-limiting, 
cumulative, chronic sensory neuropathy (De Gramont A et al, 2007). 
Several proteins and genetic markers have been described in an attempt to refine 
prognostic information and predict the benefit derived from systemic treatment. In 
particular TS protein expression, MSI, p53 expression, BRAF and TP53 mutations, 
have been described in several reports in relation to 5FU treatment, whereas ERCC1 
polymorphism, ERCC1 expression and KRAS mutations, seem to be related to 
oxaliplatin efficacy in advanced colon cancer patients (Popat S et al, 2004; Brody JR et al, 
2009; Gavin PG et al, 2012; Lin YL et al, 2012). 
In the adjuvant setting, many patients must be treated, with significant attendant 
toxicity, so that a few might benefit. As there are clearly patients who would not 
have relapsed even without adjuvant therapy, understanding the reasons for 
treatment failure and developing an ability to predict those who would benefit the 
most remain important aims in the management of curatively resected colon cancer. 
 
1.5 MSI 
As previously mentioned, MSI reflects the inability of the DNA nucleotide mismatch 
repair system (MMR) to correct errors that commonly occur during the replication of 
DNA. It is characterized by the accumulation of single nucleotide mutations and 
length alterations in repetitive microsatellite nucleotide sequences throughout the 
genome (Boland CR et al, 1998). Several studies have identified MSI as a prognostic factor 
of better survival: colon cancer patients with MSI showed in fact a significantly better 
survival if compared to MSS patients (median DFS: 76 and 54 months respectively; 
p<0.001) (Gryfe R et al, 2000), data confirmed also in patients with stage II and III colon 
cancer (Wright CM et al, 2000; Popat S el al, 2005).  
On the contrary, there are conflicting data about the role of MSI on the outcome of 
patients treated with adjuvant 5FU-based chemotherapy. It has been reported that in 
stage III colon cancer, patients who benefited from 5FU based postoperative 
treatment showed a MSS pattern, with an increase of 5 months in DFS with respect to 
MSI patients (Ribic CM et al, 2003).  However, in a retrospective analysis of 542 patients 
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enrolled in different clinical trials and randomly assigned to surgery alone or to 
adjuvant 5FU, no correlations between MSI status and 5FU therapy were found, 
either in terms of DSF (p=0.68) or OS (p=0.62) (Kim GP et al, 2007).  
Clinical and preclinical studies strongly demonstrated that MMR loss was implicated 
with resistance to cisplatin (Brown R et al, 1997; Watanabe Y et al, 2001). However, MMR 
deficiency did not affect the resistance to oxaliplatin, which formed DNA adducts, 
that are not recognised by the MMR machinery (Raymond E et al, 2002). Nevertheless, the 
predictive impact of MMR status in patients with stage III colon cancer treated with 
adjuvant oxaliplatin-based chemotherapy has been explored. It has been observed 
that patients characterized by MSI showed a great benefit from FOLFOX treatment if 
compared to MSS patients (p=0.027) (Zaanan A et al, 2011). These data were confirmed by 
another study where the benefit of MSI patients was detected in FOLFOX group and 
not in the 5FU one (p=0.01) (Zaanan A et al, 2010). 
In a recent study, validating the prognostic impact of MSI in stage III colon cancer 
patients treated with FOLFOX-based chemotherapy, no difference in the outcome 
was found between MSS and MSI patients and it has been proposed that the 
prognostic impact of MMR was dependent on tumour site (Sinicrope AF et al, 2013). 
Finally, another report showed that MMR status had no relevant predictive value for 
FOLFOX or 5FU regimens (Li P et al, 2013).  
There are still conflicting data about the role of MSI in the adjuvant setting and 
further analyses must be conducted in order to elucidate the role that MMR 
machinery can play. 
 
1.6 KRAS  
KRAS is a member of the rat sarcoma virus (ras) gene family of oncogenes (including 
KRAS, HRAS and NRAS), located on chromosome 12, encoding for the guanosine 
bis/tris phosphate (GDP/GTP)-binding protein RAS, that acts as a self-inactivating 
intracellular signal transducer (Bos JL, 1989). RAS proteins normally cycle between 
active GTP-bound (RAS-GTP) and inactive GDP-bound (RAS-GDP) conformations 
(Figure 7). 
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Figure 7: KRAS mechanism of action, active and inactive conformations (www.clarientinc.com). 
 
RAS proteins are activated by guanine nucleotide exchange factors (GEFs) which are 
recruited to protein complexes at the intracellular domain of activated receptors. 
Signalling is terminated when RAS-GTP is hydrolized to the RAS-GDP inactive 
complex by GTPase-activating proteins (GAPs) (Bos JL, 1989). 
After binding and activation by GTP, RAS recruits the protein encoded by RAF 
oncogene, which phosphorylates Mitogen-Activated Protein Kinase Kinase-1 
(MAP2K-1), thus initiating the MAPK signaling that ultimately leads to the 
expression of proteins playing important roles in cell growth, differentiation, and 
survival. Under physiological conditions, RAS-GTP levels in vivo are tightly 
controlled by the counterbalancing activities of GEFs and GAPs. 
KRAS gene mutations are one of the most common alterations in human cancers. In 
particular, this gene is mutated in over 30% of colon cancers (Edkins S et al, 2006). 
Mutations within the KRAS gene result in RAS proteins that are permanently in the 
active GTP-bound form due to defective intrinsic GTPase activity leading to a 
constitutive activation of the downstream signalling. There are limited numbers of 
mutations in the KRAS gene, and altogether more than 90% involve two specific 
codons (12 and 13). Of these, the most frequent alterations are detected in codon 12 
(about 80% of all reported KRAS mutations). Codons 12 and 13 somatic missense 
mutations lead to single amino acid substitutions in KRAS catalytic domain resulting 
in a constitutive activated form of the protein (Kosaka T et al, 2004). 
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In metastatic colon-rectal cancer, KRAS mutations are established to be predictors of 
resistance to EGFR-targeted therapies (Lièvre A et al, 2008), but nothing is known about 
their role in the adjuvant setting. 
Preclinical data suggest that response to 5FU may be predicted by KRAS mutational 
status: a transient expression of the mutant KRAS gene, but not of the wild-type 
form, enhanced 5FU-induced apoptosis in colon cancer cells. It seems to occur by the 
negative regulation of gelsolin, a protein with anti-apoptotic activity (Klampfer L et al, 
2005). 
Several analyses of recent randomized trials on metastatic colon cancer suggested 
that the KRAS gene mutation status might predict the efficacy of cytotoxic 
chemotherapy, especially for oxaliplatin-based regimens. OPUS and PRIME studies, 
which were both designed for patients to receive first-line 
oxaliplatin/5FU/leucovorin with or without anti-EGFR monoclonal antibodies, are 
good examples (Bokemeyer C et al, 2009; Douillard JY et al, 2010). These 2 studies showed that 
DFS in the KRAS mutant group lasted longer than that in the wild-type group, with 
8.6 versus 7.2 months in the OPUS study, and 8.8 versus 8.0 months in the PRIME 
study. By contrast, in CRYSTAL study, which was designed for patients receiving 
first-line irinotecan/5FU/leucovorin with or without EGFR monoclonal antibody, a 
similar phenomenon was not observed (Van Cutsem E et al, 2009). The median first-line 
DFS in KRAS-mutant and wild-type patients was 7.7 and 8.4 months, respectively. 
These studies were the starting point for other preclinical data, focused on the 
possibility to predict oxaliplatin sensitivity on the basis of KRAS mutations. In fact, in 
a recent contribution it has been observed an increased percentage of apoptosis in 
colon cancer cells transfected with a KRAS mutated vector, if compared to wild-type 
KRAS cells when both were treated with the same concentration of oxaliplatin (Lin YL 
et al, 2012). Furthermore, it has been observed that KRAS mutations in colon cancer 
cells caused the down-regulation of ERCC1 (excision repair cross-complementation 
group 1), a protein involved in the mechanism of DNA damaged recognition and 
repair (Lin YL et al, 2012). This might imply that some other unknown mechanisms 
could be responsible for the resistance to colon cancer treatment, in addition to the 
traditional RAS/RAF/MEK/ERK pathway. 
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1.7 BRAF  
BRAF gene, located on chromosome 7, encodes for a RAS effector belonging to the 
RAF family of Ser-Thr kinase proteins. BRAF gene product is recruited to the plasma 
membrane upon binding to RAS-GTP, and represents a key point in the signal 
transduction through the MAP kinase pathway (Figure 8). 
 
Figure 8: RAF and MAPK pathway (www.clarientinc.com). 
 
BRAF sequence contains three conserved regions: CR1 encodes for the putative zinc 
finger domain, CR2, where several Ser-Thr-rich regions are located, and CR3, which 
corresponds to the kinase domain. The two major regulatory sites are Thr599 and 
Ser602, phosphorylated by RAS. 
BRAF is the only RAF protein found to be frequently mutated in cancer. All 
mutations are represented by activating missense point mutations clustered in exons 
11 and 15. In particular, the most common oncogenic BRAF mutation, occurring in 
more than 90% of cases, corresponds to a T>A transversion at position 1799 of BRAF 
sequence, resulting in the Valine to Glutamate substitution at position 600 of the 
protein (V600E) within the kinase domain, thus mimicking the phosphorylation of 
Thr599 and Ser602. This change leads therefore to a mutated BRAF protein with 
elevated kinase activity, able to constitutively activated MAPK pathway (Davies H et al, 
2002). 
  Introduction   
  17  
In colon cancer, BRAF mutations occur in about 10% of cases and are frequently 
found in sporadic cancers characterized by MSI (Wang L et al, 2003). Recently, the 
correlation existing between BRAF mutations and MSI status was observed also in 
colon cancer patients who underwent FOLFOX-based adjuvant chemotherapy 
(Sinicrope AF et al, 2013). In a recent study it has been observed that BRAF mutations 
were associated with a shorter survival after recurrence in FOLFOX treated patients 
and it could be considered a link with the MSI status. Tumors deficient in the MMR 
system showed a trend towards a poor survival after recurrence (Gavin PG et al, 2012). 
 
1.8 ERCC1 
The product of ERCC1 gene belongs to the nucleotide excision repair pathway, and it 
is required for repairing DNA lesions such as those induced by UV light or formed 
by electrophilic compounds including cisplatin. Nucleotide excision repair is a highly 
conserved DNA repair pathway that repairs DNA lesions which alter the helical 
structure of the DNA molecule and interfere with DNA replication and transcription. 
Important steps in this pathway include the recognition of DNA damage and 
demarcation of the specific area affected, followed by the formation of a complex to 
unwind the damaged portion and excise it. Finally, the excised area is resynthesized 
and ligated to maintain the DNA molecule. ERCC1 forms a heterodimer with the 
xeroderma pigmentosum (XPF) complementation group F (also known as ERCC4) 
and catalyzes the 5' incision in the process of excising the DNA lesion (Figure 9). 
The nucleotide excision repair system seems to be a key pathway involved in 
mediating resistance or sensitivity to platinum chemotherapeutic agents (Martin LP et 
al, 2008). 
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Figure 9: Mechanism of DNA damage recognition and repair (Fuss JO and Cooper PK, 2006). 
 
ERCC1 complex in fact removes DNA adducts formed by platinum-based 
chemotherapies, leading to cancer cells survival. In this setting, ERCC1 can be 
considered as predictor of chemotherapy sensitivity. ERCC1 expression was 
investigated firstly in lung cancer, where platinum compounds are widely used. It 
has been observed that patients with low ERCC1 levels benefited from platinum-
based chemotherapy in non-small cell lung cancer, whereas those with high levels 
did not (Chen W and Bepler G, 2013). Also in gastric cancer, ERCC1 protein expression 
levels predict patients who more likely benefit from adjuvant cisplatin-based 
chemotherapy (De Dosso S et al, 2013). 
Regarding ERCC1 predictive role in colon cancer, it has been observed that in 
metastatic patients treated with oxaliplatin and 5FU chemotherapy, low ERCC1 
expression correlated with a significantly longer median survival as compared to 
patients with high ERCC1 levels (median DFS: 10.2 and 1.9 months respectively), 
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nonetheless the association between ERCC1 levels and the response to chemotherapy 
did not reach a statistical significance (p=0.29) (Shirota Y et al, 2001). Recently another 
study, investigating the role of ERCC1 in the adjuvant setting for stage III colon 
cancer patients, demonstrated that patients treated with oxaliplatin-based 
chemotherapy with positive ERCC1 tumors had a lower DFS (54%) and OS (60%) 
than those with negative ERCC1 tumors (72% and 78%, respectively) (p=0.009 for 
DFS values and p=0.02 for OS values). By contrast, ERCC1 status did not impact DFS 
(p=0.62) or OS (p=0.63) in 5FU group (Li P et al, 2013).  
Interestingly, in a recent study, preclinical data demonstrated that KRAS mutations 
in colon cancer cells caused ERCC1 down-regulation. KRAS knocking-down in KRAS 
mutated cancer cells led in fact to ERCC1 up-regulation and, at the same time, KRAS 
over-expression (mimic the effect of KRAS mutations) led to ERCC1 down-regulation 
and oxaliplatin sensitivity (Lin YL et al, 2012). This significant finding might imply a 
possible correlation between KRAS mutations and ERCC1 expression. 
In addition to ERCC1 expression, it has been proposed that also polymorphisms in 
ERCC1 gene may influence response to treatment in colon cancer, at least in the 
metastatic setting. For instance, the analysis of the T19007C (codon 118) 
polymorphism revealed that the response rate to FOLFOX regimen was significantly 
higher in the TT genotype group compared to CT and CC groups (61.9%, 42.3%, and 
21.4%, respectively, p=0.018). By contrast, no significant difference was observed 
when patients were treated with 5FU alone (45%, 29.2%, and 33.3%, respectively, 
p=0.407) (Viguier J et al, 2005). However, other studies suggested that patients whose 
tumours were identified with TT genotype were associated with adverse DFS 
(p=0.02) (Stoehlmacher J et al, 2004; Ruzzo A et al, 2007). Finally, another study suggested that 
CC genotype of ERCC1 codon 118 polymorphism correlates with poor prognosis 
among patients receiving adjuvant chemotherapy (Moreno V et al, 2006). Thus, the 
relationship between ERCC1 codon 118 polymorphism and clinical outcome of 
patients receiving oxaliplatin-based chemotherapy for advanced colon cancer 
remains controversial. 
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1.9 TP53 
Tumor protein 53, also known as TP53, is a tumor suppressor gene located on the 
short arm of chromosome 17. It is commonly considered the "guardian of the 
genome" for its critical function in suppressing tumorigenesis. TP53 encodes for the 
tumor suppressor protein p53, which remains in the nucleus and performs its 
function there. 
p53 deals with cells with damaged DNA by deciding the ultimate fates of these cells. 
It 'evaluates' whether the DNA damage is capable of being repaired; if so, p53 forms 
tetramers that are able to bind to the DNA and to activate the transcription of specific 
genes that can repair the damaged DNA. However, if the DNA is damaged beyond 
repair, p53 stops cells from replication and triggers the apoptosis of these cells. The 
function of p53 is not limited to the regulation of cells with damaged DNA. In fact, it 
is responsible for determining cell fate under other adverse conditions, such as lack 
of nucleotides for replication, hypoxia, and blockage of transcription (Strachan T and 
Read AP, 1999) (Figure 10). 
 
 
Figure 10: Functions of p53 (Weinberg R, The Biology of Cancer, 2007). 
 
Loss of p53 function, which occurs through inactivating mutations or deletion of the 
two alleles, is one of the most common molecular events in colon cancer 
tumorigenesis, observed in nearly 50% of cases. As a consequence, several 
translational studies have evaluated its role in prognosis and response to therapy. 
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Overall, the abnormal immunohostochemical expression of p53 and TP53 gene 
mutations are associated with increasead risk of death and a worse prognosis with 
respect to intact p53 status (Chen J et al, 2013; Sarasqueta AF et al, 2013). Furthermore, p53 
status was widely investigated because seemed to correlate with 5FU sensitivity, 
even if its role remains controversial. In stage III colon cancer patients, adjuvant 
therapy with 5FU improved 7-year survival in patients without p53 over-expression 
in respect with those patients exhibiting high p53 levels (64% versus 26%) (Ahnen DJ, 
1998). In another study, the presence of p53 mutation was not a predictive factor of OS 
(p>0.05) (Elsaleh H et al, 2000), this result was also confirmed by another preclinical study 
on cell lines where no relation between TP53 status and 5FU sensitivity at clinically 
relevant concentrations of 5FU was observed (p>0.05) (Brody JR et al, 2009). Therefore, 
the role of p53 expression and TP53 mutational status remains controversial in 
relation to 5FU adjuvant treatment. 
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Nowadays, the gold treatment for advanced colon cancer (CC) is surgicalIy resection, 
followed by adjuvant chemotherapy. The standard option consists on the 
administration of 5-Fluorouracil (5FU) and folinic acid (FA) in combination with 
oxaliplatin (FOLFOX). 
In spite of this, a proportion of patients will develop metastasis due to drug 
resistance, using a regimen that may cause potentially disabling sensory neuropathy. 
This happens because 5FU and oxaliplatin work by interfering with cellular 
functions. Oxaliplatin way of action, in particular, consists in binding to DNA and 
forming DNA adducts leading to cross-links which disrupt the structure of the DNA 
molecule and consequently run to steric changes in the helix. This alteration in the 
DNA structure leads to the activation of the cellular DNA damage recognition and 
repair system, which can result in the continued viability of the cell and, in the end, 
in treatment resistance. 
Several proteins and genetic markers have been described in an attempt to refine 
prognostic information and predict the benefit derived from systemic treatment. In 
particular TS protein expression, MSI, p53 expression, BRAF and TP53 mutations, 
have been described in several reports in relation to 5FU treatment, whereas ERCC1 
polymorphism, ERCC1 expression and KRAS mutations, seem to be related to 
oxaliplatin efficacy in advanced colon cancer patients (Popat S et al, 2004; Brody JR et al, 
2009; Gavin PG et al, 2012; Lin YL et al, 2012). 
In order to better understand how such molecular markers could predict the clinical 
outcome in patients affected by colon cancer, we planned to analyze these markers in 
a cohort of surgically resected stage III CC patients who underwent FOLFOX 
adjuvant chemotherapy. 
It is challenging to identify which patients are unlikely to benefit from adjuvant 
chemotherapy, because this would potentially spare many patients from acute and 
delayed drug-induced toxicities, and avoid the useless spending of public healthcare-
resources. 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients and Methods
  Patients and methods   
  23  
3.1 PATIENTS 
The study population consists of 230 patients from Switzerland and Argentina, 
recruited from 1998 to 2011 with curatively resected stage III colon cancer. After 
surgical resection, patients were treated with 6-months adjuvant chemotherapy, 
either with single-agent fluoropyrimidine (FP: modulated 5FU or capecitabine) or 
with oxaliplatin-based regimens (O-FP: FOLFOX or XELOX).  
Drugs were administered as follows: 
- 5FU: 5-fluorouracil 370-420 mg/m2 plus leucovorin 20-200 mg/m2 on days 
1-5, repeated every 4-5 weeks for 6 months ; 
- Capecitabine: 1000–1250 mg/m2 twice-daily on days 1-14, repeated every 3 
weeks for 6 months; 
- FOLFOX: a two-hours infusion of leucovorin 200 mg/m2 followed by a 400 
mg/m2 bolus 5FU followed by 22-hours infusion of 5FU 600 mg/m2 given 
on two consecutive days plus a two-hours infusion of 85 mg/m2 
oxaliplatin, on day 1, simultaneously with leucovorin, using a Y-infusion 
device; 
- XELOX: oxaliplatin 130 mg/m2 IV infusion over two hours (day 1 every 
three weeks) in combination with capecitabine administrated orally at dose 
of 1000 mg/m2 twice-daily (equivalent to a total daily dose of 2000 mg/m2, 
the first evening dose on day 1 and the last morning dose on day 15) given 
as intermittent treatment (three-weeks cycles consisting of two weeks of 
treatment followed by one week without treatment). 
 
3.2 CLINICAL EVALUATION 
The clinical outcome was monitored for each patient from surgery to death or to last 
follow-up date. 
After surgery and adjuvant chemotherapy, post-treatment surveillance of patients 
was performed to evaluate possible therapeutic complications, discover a recurrence 
that was potentially resectable for cure, and to identify new metachronous 
neoplasms at a pre-invasive stage. 
The surveillance during follow-up period consisted on history and physical 
examination every 3 to 6 months for 2 years, then every 6 months for 3 years and 
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then once a year; Carcino-Embryonic Antigen (CEA) test was evaluated at baseline 
and in combination with scheduled physical controls. Colonoscopy was 
accomplished at approximately 1 year after resection (or approximately 3–6 months 
post-resection if not performed preoperatively due to obstructing lesion), than once a 
year until 5 years after resection and every two years thereafter. More frequent colo-
noscopies were indicated in patients who presented a colon cancer before age 50. 
Chest, abdominal, and pelvic computed tomography scans were performed annually 
for the first 3 to 5 years, and every two years thereafter. Adverse chemotherapy 
events, such as chronic diarrhoea or incontinence or persistent neuropathy (a well 
known side effect of oxaliplatin treatment) were monitored in patients’ follow-up 
period. 
We considered the DFS as the time from the date of surgery to the date of relapse or 
other malignancies occurrence or death, whichever came first. Patients alive and free 
of relapse or other malignancies were censored at the time of last follow-up date. OS 
was defined as the period existing between surgery resection and patients’ death or 
last follow-up date. 
 
3.3 MOLECULAR ANALYSIS  
All the analyses were performed on formalin-fixed paraffin-embedded (FFPE) tissue 
sections. For immunohistochemical and molecular analyses, a single representative 
FFPE tumor tissue block, containing at least 70% of neoplastic cells was selected for 
each sample (Van Krieken JH et al, 2008). Argentinean cases were fixed in Bouin and then 
embedded in paraffin. Tumour macrodissection was performed in tumour blocks 
containing less than 70% of neoplastic cells to reduce the presence of non-neoplastic 
tissues. For microsatellite and RNA analyses, a paired healthy mucosa tissue block 
was also chosen. 
DNA extraction was performed using the QIAamp Mini kit (Qiagen, Chatsworth, 
CA, USA) while the RNeasy FFPE Kit (Qiagen) was used for RNA extraction, 
according to the manufacturer’s instructions. 
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3.4 MSI 
The status of MSI was assessed by the analysis of the microsatellite loci included in 
the panel of Bethesda (BAT 25, BAT 26, D2S123, D5S346 AND D17S250), as reported 
in the literature (Frattini M et al, 2004a). MSI was confirmed by the presence of additional 
peak(s) in tumour sample compared with the normal paired tissue. MSI was defined 
as being present when more than 30% of investigated loci showed instability. 
 
3.5 KRAS, BRAF, ERCC1 AND TP53 MUTATIONAL ANALYSIS BY 
DIRECT SEQUENCING 
KRAS, BRAF, ERCC1 and TP53 mutational status was assessed by direct sequencing 
on genomic DNA, as already reported (Frattini M et al, 2004a; Frattini M et al, 2004b; 
Stoehlmacher J et al, 2004; Liu D et al, 2005).  
In particular we investigated: 
- KRAS exon 2, including hot spots in codons 12 and 13; 
- BRAF exon 15, including hot spot in codon 600; 
- ERCC1 exon 4, including the polymorphism at codon 118; 
- TP53 exons 5, 6, 7 and 8, including hot spots in codons 175, 248, 273 and 
282. 
In the investigated exons of KRAS, BRAF and TP53 genes, more than 80-90% of 
mutations occur (Davies H et al, 2002; Samowitz WS et al, 2002; Frattini M et al, 2004a; Stoehlmacher J 
et al, 2004; www.sanger.ac.uk/genetics/CGP/cosmic/). 
Genomic DNA was amplified by Polimerase Chain reaction (PCR), purified 
(MSB®SPIN PCRapace, STRATEC Molecular, Gmbh, Berlino, Germania) and directly 
sequenced. The list of primers used is reported in Table 1. 
The direct sequencing analysis was performed by ABI Prism 3130 automated 
sequencer (Applied Biosystems, Foster City, CA, USA) as previously described  and 
the Sequencing Analysis software was used for data evaluation (Frattini M et al, 2007). 
Each sequence reaction was carried out at least twice, starting from independent PCR 
reactions. In each case, the detected mutation was confirmed in the sequence as sense 
and antisense strands. 
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Gene Exon Forward Primer Reverse Primer Annealing T
KRAS 2 TGGTGGAGTATTTGATAGTGTA CATGAAAATGGTCAGAGAA 55°C
BRAF 15 TCATAATGCTTGCTCTGATAGGA GGCCAAAAATTTAATCAGTGGA 52°C
ERCC1 4 GCAGAGCTCACCTGAGGAAC GAGGTGCAAGAAGAGGTGGA 65°C
TP53 5 TTCAACTCTGTCTCCTTCCT CAGCCCTGTCGTCTCTCCAG 62°C
TP53 6 GCCTCTGATTCCTCACTGAT TTAACCCCTCCTCCCAGAGA 62°C
TP53 7 AGGCGCACTGGCCTCATCTT TGTGCAGGGTGGCAAGTGGC 64°C
TP53 8 TTCCTTACTGCCTCTTTGCTT AAGTGAATCTGAGGCATAAC 56°C  
Table 1: Primers used for PCR reactions. 
 
3.6 ERCC1 IMMUNOHISTOCHEMICAL ANALYSIS  
The immunohistochemical (IHC) analysis was performed on 3-μm thick FFPE tissue 
section by using anti-ERCC1 (clone 8F1, dilution 1:50; ThermoScientific, 
Erembodegem, Belgium) monoclonal antibody. The analysis was performed on 
Ventana BENCHMARK® XT instrument using UltraView DAB kit (Ventana Medical 
Systems, Tucson, USA). Briefly, for epitope retrieval, slides were exposed on heat 
EDTA, then endogenous peroxidase activity was blocked by incubation with H2O2 
3% (30 min EDTA and 4 min H2O2). Primary antibody incubation was carried out for 
32 minutes at 37°C. Immunoreaction was revealed by secondary antibody incubation 
for 8 min with 3’-3’-diaminobenzidine as the chromogen, and Mayers hematoxylin as 
the counterstain. Endothelial cells of normal tonsil tissues and proliferating germinal 
centre lymphocytes were included as positive controls for ERCC1, as previously 
suggested (Olaussen KA et al, 2006; Zucali PA et al, 2011). 
Immunostaining was evaluated under a light microscope by an expert pathologist 
(Prof. Renzo Boldorini, Deparment of Medical Sciences, University of Eastern 
Piedmont, Italy). A positive staining was assigned when tumour cells showed 
nuclear reactivity. In details, the intensity of staining was scored on a scale of 0 to 3; 
with 3 indicating the higher intensity using normal tonsil tissue as positive control. 
Then we looked at the percentage of positive tumour cells, scoring as follow: 0 if 0%; 
0.1 if 1% to 9%; 0.5 if 10% to 49%; 1 if 50% or more. Finally, since to date there are no 
standardized guidelines for ERCC1 staining evaluation on colon tumours, an H-score 
usually utilized in the evaluation of ERCC1 in non-small cell lung cancer was applied 
(Olaussen KA et al, 2006). Semiquantitative H-score was obtained from intensity 
multiplied with positive cells, with values ranging from 0 to 3.  
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The median value of all H-score was chosen as the cut off point to determine positive 
or negative tissues according to the literature (Olaussen KA et al, 2006; Zucali PA et al, 2011) 
and to our previous work on gastric cancer (De Dosso S et al, 2013). 
 
3.7 ERCC1 ANALYSIS BY REAL-TIME PCR 
To analyze ERCC1 gene expression, a fluorescence-based real-time procedure 
(StepOne™ Real-Time PCR System; Applied Biosystems) was adopted, using the 
protocol previously described (Gibson UE et al, 1996; Heid CA et al, 1996; Sørby LA et al, 2010; 
Kheirelseid EA et al, 2010). Pol2RA was chosen as internal reference gene. 
Total RNA was transcribed into cDNA using the High Capacity RNA-to-cDNATM 
Master Mix protocol (Applied Biosystems). Real Time PCR was performed in the 
CFX96™ Real Time System (Bio-Rad, Hercules, CA, USA). Taqman Gene Expression 
Master Mix and Taqman assays probes (POL2RA probe: Hs00172187_m1 and 
ERCC1 probe: Hs01012161_m1) were purchased from Applied Biosystems. 
Each sample was analyzed in triplicate. Final results were determined by the formula 
2-ΔΔCt, which standardizes the target with the reference gene in both tumour and 
normal tissue (Livak KJ and Schmittgen TD, 2001). The median value of all scores was used 
as threshold line separating ERCC1 overexpressing (higher values) from ERCC1 
normally expressing (lower values) cases. 
 
3.8 STATISTICAL ANALYSES 
A two-tailed Fisher’s exact test was used to calculate the p values for the association 
among variables. Level of significance was set at p=0.05. The DFS and OS analyses 
were performed according to the Kaplan–Meier method, and survival curves were 
compared using the log-rank test. Data were analyzed using the IBM SPSS Statistics 
20 package. 
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4.1 PATIENTS CHARACTERISTICS 
Two-hundred and thirty patients with advanced colon cancer (stage III), were 
enrolled in this study. The population included 103 women and 127 men. The 
median age at diagnosis was 62 years (range: 22-82). One-hundred and six patients 
received 5FU as single-agent, whereas the remaining 124 received FOLFOX. The 
presence of relapse was observed in 77 (33%) cases, 39 of whom were treated with 
only fluoropyrimidine and 38 received also the oxaliplatin. All patients’ 
characteristics are reported in Table 2. The median DFS and OS follow-up period 
were 45.9 months (range: 1.7-177 months) and 52.4 (range: 2.5-177 months) 
respectively. 
 
Patients characteristics (N=230) Number of cases Percentage (%)
Age
      > 65 96 42
      ≤ 65 134 58
Gender
      male 127 55
      female 103 45
Treatment
     5FU 106 46
     FOLFOX 124 54
Relapse
      yes 77 33
      no 153 67  
Table 2: Patients’ clinical-pathological characteristics. 
 
Age and gender were correlated with the DSF and OS for the entire cohort, but no 
statistical significance was observed. 
By stratifying the population for the two treatments, we found that patients who 
received FOLFOX (median DFS and OS: 51.3 and 55.4 months, respectively) seem to 
get more benefit by chemotherapeutic treatment if compared to patients treated with 
5FU alone (median DFS and OS: 41.6 and 49.3 months, respectively), even if those 
results did not reach a statistically significant value, in both DFS (p=0.54) (Figure 11A) 
and OS (p=0.22) (Figure 11B).  
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Figure 11: DFS (A) and OS (B) for the entire population stratified for the received treatment. 5FU= 5-
fluorouracil; FOLFOX= 5-fluorouracil plus oxaliplatin. 
 
4.2 MOLECULAR ANALYSES 
MSI, KRAS, BRAF, ERCC1 and TP53 molecular results are summarized in Table 3. 
Every molecular marker was correlated with the survival probability, in order to 
verify if a prognostic value could be associated to each one. 
 
Marker (N) Molecular alterations Number of alterations Percentage (%)
MSI 26 12
MSS 183 88
Mutated 65 28
Wild-type 164 72
Mutated 21 9
Wild-type 203 91
TT genotype 69 31
CT genotype 105 48
CC genotype 47 21
Mutated 83 44
Wild-type 106 56
MSI   
(N=209)
KRAS 
(N=229)
BRAF 
(N=224)
TP53 
(N=189)
ERCC1 
(N=221)
 
Table 3: Molecular results. N = number of cases evaluable for a given marker. 
 
4.2.1 MSI 
Microsatellite status was assessed in 209 cases, because 21 were not evaluable. The 
results showed MSS in 183 cases (88%) whereas MSI was detected in the remaining 
26 cases (12%) (Table 3). 
The correlation with the DFS (p=0.17) revealed a better prognostic trend for patients 
showing MSI if compared to those with MSS, as reported in the Kaplan Meyer curve 
A B 
p=0.22 p=0.54 
Adjuvant regimen                5FU            FOLFOX Adjuvant regimen                5FU            FOLFOX 
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(Figure 12A), even if this result did not reach a statistical significance. On the contrary, 
the correlation with the OS (p=0.48) was not statistical significant (Figure 12B). 
 
       
Figure 12: DFS (A) and OS (B) for MSI and MSS patients. 
 
4.2.2 KRAS 
The characterization of KRAS mutational status was not possible in 1 case. We 
identified 65 (28%) mutations, 52 in codon 12 and 13 in codon 13 (Table 3). In 
particular, in codon 12 we detected the following alterations: G12D in 23 cases, G12V 
in 13 cases, G12A in 6 cases, G12C in 5 cases, G12S in 4 cases and G12R just in 1 case. 
Regarding codon 13, we identified the G13D alteration in all the 13 cases. 
By correlating KRAS status with clinical follow-up, KRAS mutations confer a worse 
prognosis to advanced colon cancer patients, borderline for the DFS (p=0.07) (Figure 
13A) and statistically significant for the OS (p=0.004) (Figure 13B). 
 
      
Figure 13: DFS (A) and OS (B) for KRAS mutated (Mut) and wild-type (WT) patients. 
 
p=0.17 p=0.48 
p=0.07 p=0.004 
A B 
A B 
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4.2.3 BRAF 
We performed BRAF mutational analysis in 224 cases, because 6 cases were not 
evaluable. We detected 21 alterations (9%) (Table 3), in all cases the mutation identified 
was the classical V600E change. 
The correlation between BRAF mutational status and clinical follow-up was not 
statistical significant, for both DFS (p=0.40) (Figure 14A) and OS (p=0.53) (Figure 14B). 
 
       
Figure 14: DFS (A) and OS (B) for BRAF mutated (Mut) and wild-type (WT) patients. 
 
4.2.4 ERCC1 
The characterization of codon 118 (AAT/AAC) polymorphism was possible in 221 
cases. We identified TT genotype in 69 patients (31%), CT genotype in 105 patients 
(48%) and the CC variant in 47 cases (21%) (Table 3). Therefore, the T allele was present 
in 79% of cases and the C allele in 69% of patients. The correlation with the clinical 
data is on-going. 
 
4.2.5 TP53 
TP53 analysis was performed in 189 cases as 41 were classified as not evaluable. 
Overall, we identified 83 mutations (44%) (Table 3). In particular, we detected the vast 
majority of alterations in exons 5 and 7. Seventy-seven cases displayed one mutation, 
whereas 6 patients carried two alterations. The most frequent identified mutations 
were R175H (in exon 5) in 8 cases and G245S, R248Q, R248W (all changes in exon 7) 
and R306X (in exon 8) in 4 cases each (Table 4). The presence of a frameshift mutation 
(due to a deletion or an insertion of one or more nucleotides) was detected in 11 
A B 
p=0.40 p=0.53 
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cases, in particular: 2 in exon 5, 2 in exon 6, 4 in exon 7 and 3 in exon 8. The 
remaining mutations identified are reported below (Table 4). 
The correlation with the clinical follow-up is on-going. 
 
exon 5 exon 6  exon 7 exon 8
R152S R196X Y233X G266R
R158L R213X (2) Y234H E271K
A159V  H214R Y236C R273C (2)
A161T V216M M237I R273H
Y163C V220C M237V V274F (2)
Y163N Y220H C238Y V274L
Q165X V225G N239D P278L,
E171X FS (2) N239S R280K
V172F C242F D281Y
 R174W G244D  R282W (2)
R175H (8) G245C (2) R283H
C176G G245D (2) E285K
C176R G245S (4) K305M
H178Y R248Q (4) R306X (4)
H179L R248W (4) FS (3)
 H179Y FS (4)
FS (2)
TP53
 
Table 4: List of TP53 mutations identified in our cohort, the numbers in brackets correspond to the 
number of patients with that alteration. FS = frameshift. 
 
4.3 ERCC1 EXPRESSION 
ERCC1 expression levels were analyzed both by IHC and by real-time PCR. The 
results are reported in Table 5. 
 
ERCC1 detection Positive cases Percentage
40%
49%
IHC
Real-Time PCR
88/218
102/207
 
Table 5: ERCC1 positive expression levels detected by IHC and by real-time PCR. 
 
4.3.1 IHC 
The ERCC1 protein expression analysis, studied by IHC, was successful in 218 cases 
as 12 cases were not evaluable. At first, we evaluated for each patient the intensity of 
staining, on the basis of pathologist’s evaluation: 79 were classified as 0, 64 as 1+, 46 
as 2+ and 29 as 3+. Then we considered the percentage of cells recognized as positive 
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to ERCC1 staining (from 0% to 100%). By combining the two scores we obtained H-
values, ranging from 0.1 to 3. On the basis of the literature, assuming the median H-
score value (0.5 in our cohort) as the cut-off point, 88 (40%) were considered positive 
(>0.5) (Figure 15A) and 130 (60%) were classified as negative (≤0.5) for ERCC1 protein 
expression (Figure 15B) (Table 5).  
 
   
Figure 15: Examples of ERCC1 protein expression, positive, score 3 (A) and negative, score 0 (B). 
 
When we correlated the clinical follow-up with IHC data, we classified the cases on 
the basis of two parameters: in the first one we considered ERCC1 negative cases 
only those with ERCC1 score 0 (and then we performed the correlation with the 
group of score 1+, score 2+, score 3+), in the second one we considered as negative 
those cases with score 0 and 1+. The results were not statistically significant in both 
situations. Finally, we correlated the clinical follow-up with the median H-score (0.5), 
and also with these parameters we did not find any statistical difference (p=0.40 for 
DFS and p=0.55 for OS) (Figure 16A,B). 
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Figure 16: DFS (A) and OS (B) for patients exhibiting low (≤0.5) and high (>0.5) ERCC1 protein 
expression levels. 
 
4.3.2 REAL-TIME PCR 
The analysis of ERCC1 mRNA expression was successful in 207 patients. Values 
ranged from 0.2 to 16.8, with a median value of 1.20. According to the literature, 
using the median value as the cut-off point, in our cohort 102 (49%) were considered 
overexpressing ERCC1 (values higher than 1.20), whereas in 105 (51%) cases ERCC1 
resulted as down-regulated (Table 5). By correlating the real-time results with the 
clinical follow-up, we observed a trend toward a better DFS (p=0.11) for those 
patients showing lower ERCC1 mRNA levels (Figure 17A) and there was no difference 
in the OS (p=0.37) for patients characterized by ERCC1 down- or up- regulation 
(Figure 17B). 
 
       
Figure 17: DFS (A) and OS (B) for patients exhibiting low (≤1.20) and high (>1.20) ERCC1 mRNA 
levels. 
 
A B 
p=0.40 p=0.55 
ERCC1 RT3                       <=1.20           >1.20 ERCC1 RT3                       <=1.20           >1.20 
A B 
p=0.11 p=0.37 
Results 
 
 
  35  
4.3.3 CORRELATION BETWEEN ERCC1 PROTEIN AND mRNA LEVELS 
When we correlated the results of ERCC1 protein expression by IHC with those of 
ERCC1 mRNA expression by Real-Time PCR, we did not find any association, also 
taking into account all the possible immunohistochemical classifications. 
 
4.4 MOLECULAR MARKERS CORRELATIONS 
In our cohort, we can confirm the mutual exclusivity existing between KRAS and 
BRAF mutations: in fact, all 65 KRAS mutated cases were BRAF wild-type, and all 9 
BRAF mutated cases showed a KRAS wild-type sequence. 
By correlating microsatellite status and BRAF mutations, we were able to identify a 
statistically significant association between the two molecular markers (p=0.0052, 
two-tailed Fisher’s exact test) (Table 6).  
 
BRAF mutated BRAF wild-type p value
MSI 8 18
MSS 9 168
p=0.0052
 
Table 6: Microsatellite pattern and BRAF mutational status association (two-tailed Fisher’s exact test). 
 
No association was found between KRAS mutations and ERCC1 expression, in both 
protein (p=0.28) (Table 7) and mRNA (p>0.99) (Table 8) levels. 
 
KRAS mutated KRAS wild-type p value
IHC>0.5 21 67
IHC≤0.5 40 89
p=0.28
 
Table 7: ERCC1 protein expression (detected by IHC, using H-score classification) and KRAS 
mutational status association (two-tailed Fisher’s exact test). 
 
KRAS mutated KRAS wild-type p value
RT>1.20 31 70
RT≤1.20 32 73
p>0.99
 
Table 8: ERCC1 mRNA levels (detected by real-time PCR) and KRAS mutational status association 
(two-tailed Fisher’s exact test). 
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4.5 MOLECULAR MARKERS AND CLINICAL OUTCOME 
The molecular results for the entire cohort were then correlated with the clinical 
outcome of patients treated with the two different modalities, 5FU alone or in 
addition to oxaliplatin (FOLFOX). The detailed correlations are reported below. 
 
4.5.1 MSI and treatment 
We identified MSI in 12 (13%) patients treated with 5FU and in 14 (12%) treated with 
FOLFOX. By correlating microsatellite status and 5FU treatment, the result we 
obtained was not statistical significant for DFS (p=0.16) (Figure 18A) and OS (p=0.37) 
(Figure 18B), but in the former a trend toward a better outcome was found in patients 
showing MSI. 
 
       
Figure 18: DFS (A) and OS (B) for MSI and MSS in 5FU treated patients. 
 
By correlating microsatellite status and FOLFOX treatment, there was no difference 
in the clinical outcome, for both DFS (p=0.67) (Figure 19A) and OS (p=0.86) (Figure 19B) 
for patients exhibiting MSI or MSS. 
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Figure 19: DFS (A) and OS (B) for MSI and MSS in FOLFOX treated patients. 
 
4.5.2 KRAS and treatment 
Above all, we identified 31 (30%) KRAS mutations in the 5FU group and 34 (27%) in 
FOLFOX cases.  
By correlating KRAS mutational status with the clinical outcome of patients treated 
with 5FU, a statistical significant worse DFS (p=0.04) (Figure 20A) and a trend toward a 
worse OS (p=0.07) (Figure 20B) were observed in KRAS mutated patients. The median 
DFS and OS were 46.0 and 56.1 months, respectively, in KRAS mutated patients, and 
57.1 and 62.0 months, respectively, in KRAS wild-type cases. 
 
       
Figure 20: DFS (A) and OS (B) for KRAS mutated (Mut) and wild-type (WT) patients treated with 5FU. 
 
Then, we correlated KRAS gene status with the outcome of patients who were treated 
with FOLFOX regimen. 
DFS (p=0.62) (Figure 21A) and OS (p=0.77) (Figure 21B) were not statistically different for 
mutated and wild-type KRAS patients treated with FOLFOX: the median DFS and 
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OS were 43.7 and 48.9 months, respectively, in the mutated group, and 44.4 and 49.6 
months, respectively, in wild-type patients.  
 
       
Figure 21: DFS (A) and OS (B) for KRAS mutated (Mut) and wild-type (WT) patients treated with 
FOLFOX. 
 
Stratifying the population on the basis of KRAS mutational status, we observed that 
in wild-type KRAS cases, DFS (p=0.78) (Figure 22A) and OS (p=0.68) (Figure 22B) did not 
significantly differ between the two treatment modalities: the median DFS and OS 
were 44.4 and 49.6 months, respectively, in FOLFOX group, and 57.1 and 62.0 
months, respectively, for the 5FU regimen.  
 
      
Figure 22: DFS (A) and OS (B) for KRAS wild-type cases stratified for the received treatment. 5FU= 5-
fluorouracil; FOLFOX= 5-fluorouracil plus oxaliplatin. 
 
In KRAS mutated cases, a trend toward better DFS (p=0.28) (Figure 23A) and OS 
(p=0.20) (Figure 23B) was observed in FOLFOX treated patients with respect to 5FU 
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group, although without reaching statistical significance. The median DFS and OS 
were 43.7 and 48.9 months, respectively, in FOLFOX group, and 46.0 and 56.1 
months, respectively, in 5FU group. 
 
       
Figure 23: DFS (A) and OS (B) for KRAS mutated cases stratified for the received treatment. 5FU= 5-
fluorouracil; FOLFOX= 5-fluorouracil plus oxaliplatin. 
 
4.5.3 BRAF and treatment 
We identified 9 (8.6%) BRAF mutations in the 5FU group and 12 (10%) in the 
FOLFOX cases. We correlated BRAF mutational status in both 5FU and FOLFOX 
group. Our results did not show statistical difference in the clinical outcome for 
mutated or wild-type BRAF patients in 5FU regimen, for both DFS (p=0.70) (Figure 
24A) and OS (p=0.55) (Figure 24B). 
 
       
Figure 24: DFS (A) and OS (B) for BRAF mutated (Mut) and wild-type (WT) patients, treated with 
5FU. 
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Also in FOLFOX group, DFS (p=0.43) (Figure 25A) and OS (p=0.78) (Figure 25B) were not 
statistical different for BRAF mutated or wild-type patients. 
 
       
Figure 25: DFS (A) and OS (B) for BRAF mutated (Mut) and wild-type (WT) in FOLFOX treated 
patients. 
 
4.5.4 ERCC1 and treatment 
Looking at immunohistochemical results, taking into account the H-score, we 
identified 64 (66%) patients in the 5FU group and 66 (55%) in the FOLFOX group 
showing a down-regulation of ERCC1 expression levels (H score ≤0.5). By correlating 
ERCC1 protein expression levels with 5FU patients’ clinical outcome, no statistical 
difference was identified between ERCC1 up- or down- regulation in both DFS 
(p=0.47) (Figure 26A) and OS (p=0.89) (Figure 26B). 
 
       
Figure 26: DFS (A) and OS (B) for ERCC1 negative (≤0.5) and positive (>0.5) expression detected by 
immunohistochemistry in 5FU treated patients. 
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Same absence of statistical association between ERCC1 immunohistochemical results 
and clinical outcome was observed in FOLFOX treated patients. The survival 
probability did not differ between ERCC1 positive (>0.5) and negative (≤0.5) patients, 
in both DFS (p=0.44) (Figure 27A) and OS (p=0.36) (Figure 27B). 
 
       
Figure 27: DFS (A) and OS (B) for ERCC1 negative (≤0.5) and positive (>0.5) expression detected by 
immunohistochemistry in FOLFOX treated patients. 
 
Considering patients showing low levels (≤0.5) of ERCC1 protein and correlating 
them with the clinical outcome, we found no statistical difference between 5FU and 
FOLFOX treated patients for both DFS (p=0.58) (Figure 28A) and OS (p=0.79) (Figure 28B). 
 
       
Figure 28: DFS (A) and OS (B) for cases showing low (≤0.5) ERCC1 protein expression level, stratified 
for the received treatment. 5FU= 5-fluorouracil; FOLFOX= 5-fluorouracil plus oxaliplatin. 
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Also observing clinical outcome for patients showing ERCC1 protein high levels 
(>0.5) no statistical difference was detected between 5FU and FOLFOX treatment, for 
both DFS (p=0.76) (Figure 29A) and OS (p=0.17) (Figure 29B). 
 
       
Figure 29: DFS (A) and OS (B) for cases showing high (>0.5) ERCC1 protein expression level, stratified 
for the received treatment. 5FU= 5-fluorouracil; FOLFOX= 5-fluorouracil plus oxaliplatin. 
 
Similar results were obtained by using the 2 other ERCC1 scores.  
Looking at the results obtained with the real-time PCR and considering the median 
value (1.20) as the cut-off point, we identified 42 (45%) patients in the 5FU group and 
63 (55%) in the FOLFOX group showing a down-regulation (≤1.20) of ERCC1 mRNA 
levels.  
The statistical analysis showed no difference in DFS (p=0.91) (Figure 30A) and OS 
(p=0.49) (Figure 30B) for 5FU treated patients with low (≤1.20) or high (>1.20) ERCC1 
mRNA levels. 
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Figure 30: DFS (A) and OS (B) for ERCC1 negative (≤1.20) and positive (>1.20) mRNA expression 
levels detected by real-time PCR in 5FU treated patients. 
 
The statistical analysis in FOLFOX treated patients showed a trend toward a better 
DFS (p=0.17) (Figure 31A) in patients characterized by low (≤1.20) ERCC1 mRNA 
levels. On the other hand, no statistical difference in OS (p=0.36) (Figure 31B) was 
observed for patients showing low or high ERCC1 mRNA levels.  
 
       
Figure 31: DFS (A) and OS (B) for ERCC1 negative (≤1.20) and positive (>1.20) mRNA expression 
levels detected by real-time PCR in FOLFOX treated patients. 
 
Considering patients showing low ERCC1 mRNA levels (≤1.20) and correlating them 
with the clinical outcome, we found no statistical difference between 5FU and 
FOLFOX treated patients, even if we could observed a trend toward a better outcome 
in favour of FOLFOX treated patients, for both DFS (p=0.28) (Figure 32A) and OS 
(p=0.13) (Figure 32B) 
A 
A B 
B 
p=0.17 
p=0.91 p=0.49 
p=0.36 
FOLFOX FOLFOX 
5FU 5FU 
Results 
 
 
  44  
       
Figure 32: DFS (A) and OS (B) for cases showing low (≤1.20) ERCC1 mRNA levels, stratified for the 
received treatment. 5FU= 5-fluorouracil; FOLFOX= 5-fluorouracil plus oxaliplatin. 
 
Observing clinical outcome for patients showing high (>1.20) ERCC1 protein mRNA 
levels no statistical difference was detected between 5FU and FOLFOX treatment, for 
both DFS (p=0.83) (Figure 33A) and OS (p=0.81) (Figure 33B). 
 
       
Figure 33: DFS (A) and OS (B) for cases showing high (>1.20) ERCC1 mRNA levels, stratified for the 
received treatment. 5FU= 5-fluorouracil; FOLFOX= 5-fluorouracil plus oxaliplatin. 
 
4.5.5 Other correlations 
The correlations between ERCC1 polymorphism at codon 118 and TP53 mutational 
status with clinical data are under evaluation. 
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Nowadays the possibility to select patients that could benefit from a  specific therapy 
is becoming essential, in particular in oncology where often we assisted to the onset 
of treatment resistance events and adverse side effects. Main efforts are aimed in the 
research of new potential prognostic and predictive markers, in particular for those 
diseases that are classified as the big killers, in order to better address patients to the 
proper chemotherapeutic treatment. 
Colon cancer is the second cause of cancer-related death, accounting for over one 
million new cases per year worldwide (Parkin DM et al, 2005). In most patients it is 
diagnosed when still confined to the bowel and in these cases surgery resection is the 
main therapeutic option. In cases of advanced colon cancer, with a lymph node 
involvement, adjuvant chemotherapy is mandatory (Wolmark N et al, 1988). The current 
standard of care for advanced (stage III) colon cancer patients is surgical resection, 
followed by 6-months 5FU-based chemotherapy or, more frequently, by oxaliplatin-
based chemotherapy (Andrè T et al, 2004). However, platinum-based treatments are 
associated with adverse side effects and, therefore, it is of high importance to find 
molecular markers able to identify patients who cannot benefit from this therapy, in 
order to avoid inefficacious treatments. 
On this purpose we planned to analyze 230 patients from Switzerland and 
Argentina, characterized by a stage III colon cancer, who underwent adjuvant 
chemotherapy with 5FU alone, or in combination with oxaliplatin (FOLFOX), in 
order to establish the potential effect of some molecular markers on the two received 
treatments.   
Patients characteristics of our cohort were in line with those reported in literature: 
the median age at diagnosis was 62 and the number of males and females was 
approximately similar. Furthermore, our cohort was equally subdivided in the two 
groups: 106 patients received 5FU as single agent and 124 were treated with FOLFOX 
regimen. This balanced distribution between the two chemotherapeutic options 
allowed us to make reliable considerations on the basis of statistical correlation with 
the clinical outcome in both groups of patients. The percentage of relapse was about 
50% in both groups of patients and the median follow up was 50 months in the 
whole cohort.  
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As already reported in other studies, where an advantage in survival was observed 
for FOLFOX treatment when compared to 5FU regimen, we noticed a better DFS 
(51.3 months) and OS (55.4 months) for FOLFOX treated patients if compared to DFS 
(41.6 months) and OS (49.3 months) in the 5FU group (Andrè T et al, 2004; Kuebler JP et al, 
2007). However, the values are not statistically different, even if a slight trend is 
observed for OS (p=0.22), where the two curves corresponding to the two treatments 
appear well separated.  
Overall, we must underline that the procedures with whom our cases had been 
processed were different between Argentinean and Swiss cases. The tumors of first 
group were fixed in Bouin while those of the second one in formalin. During 
molecular tests, we observed a high number of failures, if we compare our results 
with the median of the literature, in particular in the cohort recruited in Argentina. 
Starting with molecular analyses, MSI is a predictor of good prognosis in a non-
selected population of colon cancer including all stages. In our cohort, we observed 
that patients characterized by MSI (12%) showed a better DFS if compared to MSS 
cases. The value did not reach a statistical significance (p=0.17), in our opinion only 
due to the low number of analyzed cases. Therefore, we suggest that also in 
advanced stage III colon cancers, the evaluation of MSI status may be useful for the 
identification of patients with better prognosis. 
On the contrary, the role of MSI in the prediction of efficacy of chemotherapy is still 
debated. In fact, it has been observed that in stage III colon cancer, patients who 
benefited the most from 5FU treatment showed a MSS pattern, with an increase of 5 
months the DFS with respect to MSI patients (Ribic CM et al, 2003). On the contrary, in 
another study no correlation between MSI and 5FU treatment was observed, for both 
DFS and OS (Kim GP et al, 2007). Regarding the potential association of MSI with 
FOLFOX regimen, controversial data exist: two studies observed a better clinical 
outcome in MSI patients if compared to MSS cases, whereas two other works 
reported no differences in the clinical outcome for MSI and MSS patients (Zaanan A et 
al, 2010; Zaanan A et al, 2011; Li P et al, 2013; Sinicrope AF et al, 2013). 
In our cohort, we observed the trend for a better DFS in MSI patients treated with 
5FU if compared to MSS patients (p=0.16). On the contrary, there was no difference 
in the clinical outcome for MSI and MSS patients in the FOLFOX group (p=0.67 and 
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p=0.86, DFS and OS respectively). Therefore our results are in contrast with those 
reported in literature by Ribic and Kim regarding the role played by MSI in 5FU 
regimen but we confirmed the absence of a relevant role of MSI in FOLFOX cases, as 
reported by Li and Sinicrope (Ribic CM et al, 2003; Kim GP et al, 2005; Li P et al, 2013; Sinicrope AF 
et al, 2013).  In conclusion, on the basis of all the assumptions reported to date, the role 
that MSI could play in the prediction of 5FU and FOLFOX treatments remains 
controversial. 
A marker strictly associated with MSI is BRAF. In fact, it has been widely 
demonstrated that BRAF mutations, occurring in about 10% of colon cancer cases, are 
more frequently associated with MSI (Wang L et al, 2003; Sinicrope AF et al, 2013). Our results, 
although obtained in a selected cohort of cases (i.e. only those with lymph nodes 
involvement), confirmed the data of the literature of both percentage of alteration 
and association with MSI (p=0.005). On the other hand, it has reported that 
mutations in BRAF gene usually confer a worse prognosis to colorectal cancer 
patients (Fariña-Sarasqueta A et al, 2010; Ogino S et al, 2011; Yokota T et al, 2011). About this point, 
in our cohort we did not find any statistical association, probably due to the 
extremely low number of mutated cases or to the fact that our patients’ series 
includes only advanced cases. 
As far as the correlation with treatments efficacy is concerned, in a recent study it has 
been observed that BRAF mutations were associated with a shorter survival after 
recurrence in FOLFOX-treated patients when compared to BRAF wild-type cases 
(Gavin PG et al, 2012). In our cohort, we did not observe any statistical difference in terms 
of DFS and OS between BRAF mutated and wild-type patients in both 5FU and 
FOLFOX groups. Therefore, the investigation of additional (and larger) cohorts is 
required to shed light on the role played by BRAF mutations in FOLFOX-treated 
patients. 
We then focused our attention on another molecular marker, KRAS, on the basis of 
recent reports about the potential predictive role of KRAS mutations in oxaliplatin-
based treated patients (Bokemeyer C et al, 2009; Douillard JY et al, 2010). 
The rate of KRAS mutations in our cohort was 28%, and the vast majority were 
identified in codon 12 (52/65). Percentage of alterations and types of mutations are in 
line with those reported in literature (Edkins S et al, 2006). 
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When we matched the KRAS mutational status with clinical data of the whole cohort 
represented by advanced colon cancer patients, we observed that mutations in KRAS 
gene conferred a worse prognosis with respect to KRAS wild-type cases. The 
correlation with clinical outcome revealed in fact a trend towards a worse DFS 
(p=0.07) and a statistical worse OS (p=0.004) in KRAS mutated patients.  
Then, we looked at the role of KRAS with respect to chemotherapies. The number of 
KRAS mutations identified in our cohort was balanced in 5FU and FOLFOX groups: 
31 and 34 alterations, respectively. In 5FU-treated patients, we noticed a significantly 
worse DFS (p=0.04) and a trend towards a worse OS (p=0.07) for KRAS mutated 
patients if compared to those with a KRAS wild-type tumor. On the contrary, in 
FOLFOX group no difference was found on the basis of KRAS mutational status for 
both DFS (p=0.62) and OS (p=0.77). Furthermore, by stratifying our population on 
the basis of KRAS gene status, no difference was observed in wild-type patients 
treated with 5FU if compared to those treated with FOLFOX. On the contrary, in 
KRAS mutated patients a trend towards a worse DFS (p=0.28) and OS (p=0.20) was 
detected in 5FU group when compared to FOLFOX-treated patients. Our results 
suggest that curatively resected stage III colon cancer patients exhibiting wild-type 
KRAS status might benefit from 5FU alone. On the contrary, an oxaliplatin-
containing regimen should be recommended in KRAS mutated patients. 
Our results are supported by those observed in a preclinical study, where the 
percentage of apoptotic cells, under oxaliplatin treatment, transfected with a KRAS 
mutated vector, was significantly higher if compared to KRAS wild-type cells, thus 
suggesting that KRAS mutations may represent a predictor of oxaliplatin sensitivity 
in colon cancer (Lin YL et al, 2012). A similar correlation was also observed in recent 
randomized trials (OPUS and PRIME) on metastatic colorectal cancer (Bokemeyer C et al, 
2009; Douillard JY et al, 2010). 
The reason of the role of KRAS on the efficacy of oxaliplatin in colon cancer seems to 
be due to a link with ERCC1. In fact, at preclinical level, it has been shown that KRAS 
mutations are associated with ERCC1 down-regulation (Lin YL et al, 2012). The possible 
correlation between KRAS and ERCC1 is not known yet. Those Authors proposed 
two possible mechanisms: 1) KRAS mutations may be responsible of an epigenetic 
mechanism leading to ERCC1 promoter hypermethilation, causing a decrease of 
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ERCC1 expression; 2) there is a hypothetical unknown-ERCC1-activating factor that 
is inhibited by KRAS mutations, resulting in ERCC1 down-regulation. Therefore, we 
investigated ERCC1 expression at both protein (by IHC) and mRNA (by real-time 
PCR) level in our cohort of advanced colon cancer. In our study we did not confirm 
any correlation between KRAS mutation and ERCC1 expression, both at protein (also 
using different evaluation criteria) and mRNA level. The reason for this discordance 
is probably due to the fact that there are no guidelines helping in ERCC1 evaluation 
for both IHC and mRNA analysis, making ERCC1 assessment equivocal. In IHC 
analysis we used in fact scores on the basis of previous studies on lung cancer, and in 
gastric cancer, made by our group (Olaussen KA et al, 2006; De Dosso S et al, 2013). 
Alternatively, we can think that the correlation between KRAS mutations and ERCC1 
is valid only in specific cellular models or, at least, not in patients with a stage III 
colon cancer. 
In general, it has been proposed that ERCC1 can play a predictive role for the 
identification of patients who may benefit from adjuvant chemotherapies and 
therefore it is useful to investigate this marker per se and not only in relation to KRAS 
mutational status. We identified positive ERCC1 protein expression levels in 40% of 
cases detected by IHC and in 49% of cases we identified ERCC1 positive mRNA 
levels, and our data are in line with those reported in literature (Li P et al, 2013). 
By correlating these molecular data with the clinical outcome in the whole cohort, we 
observed no statistical differences in DFS and OS when patients showed high or low-
ERCC1 levels, in both protein and mRNA evaluation. 
In our cohort we identified no difference in the clinical outcome for patients 
exhibiting ERCC1 high or low protein expression levels detected by IHC in both 5FU 
and FOLFOX groups. On the contrary, we detected a trend toward a better DFS 
(p=0.17) and OS (p=0.36) in FOLFOX treated patients when ERCC1 mRNA levels 
were negative. Our results are confirmed by the lonely work published on ERCC1 in 
FOLFOX-treated patients (including a South-Eastern Asian cohort) (Li P et al, 2013). In 
this study, in fact, ERCC1 levels resulted to be highly predictive of which patients 
will benefit from the addition of oxaliplatin to 5FU for stage III colon cancer, in 
particular ERCC1 down-regulation corresponded to a better DFS (p=0.009) and OS 
(p=0.02) in oxaliplatin-based treated patients (Li P et al, 2013). This is simply explained 
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by the fact that ERCC1 repairs oxaliplatin-induced adducts, so low ERCC1 levels 
result in a greater and more efficent oxaliplatin action. The association between 
ERCC1 expression and platinum-based chemotherapy response was also observed in 
lung cancer and in gastric cancer (Chen W and Bepler G, 2013; De Dosso S et al, 2013). Therefore 
we could propose also ERCC1 expression analysis as a new marker for a better 
selection of patients to be addressed to oxaliplatin-based chemotherapy; but, of 
course, analyses of larger cohorts must be performed. 
In addition to protein and mRNA levels, it has been suggested that a polymorphism 
occurring at codon 118 (AAT/AAC) of the ERCC1 gene, may correlate with the 
ability of ERCC1 to repair the adducts induced by platinum-based compounds and 
its role as a marker of a better outcome in patients with colon cancer treated with 
oxaliplatin-based schemes was supported in several studies (Stoehlmacher J et al, 2004; 
Viguier J et al, 2005; Ruzzo et al, 2007). However, the results are controversial: in a study it 
has been reported that TT genotype seemed to be associated with the most 
favourable survival, while the other two above-mentioned studies observed a 
significant correlation between CC genotype and better survival (Stoehlmacher J et al, 2004; 
Viguier J et al, 2005; Ruzzo et al, 2007). In our cohort, the TT genotype was detected in 31% of 
cases, the CT genotype in 48% of patients and the CC variant in 21% of the whole 
cohort, and these percentage are in line with those reported (Viguier J et al, 2005). The 
correlation between ERCC1 genotype and clinical outcome in our cohort is now 
under evaluation. 
Moreover, we also investigated the mutational status of TP53, because in the 
literature it has been proposed an increased risk of death and a worse prognosis 
(p<0.001) in those patients exhibiting TP53 mutations (Chen J et al, 2013; Sarasqueta AF et al, 
2013), data not confirmed by another study where the presence of TP53 mutations in 
colon cancer patients, was not a predictive factor of OS (p>0.05) (Elsaleh H et al, 2000). 
Furthermore, it has been reported that stage III colon cancer patients who underwent 
adjuvant therapy with 5FU showed an improvement of 7-years survival when p53 
was not over-expressed in respect to those patients exhibiting high p53 levels (Ahnen 
DJ, 1998). On the contrary, in a preclinical study on cell lines, no relation between TP53 
status and 5FU sensitivity was observed (p>0.05) (Brody JR et al, 2009). Therefore, the 
relationship between TP53 status and the clinical outcome in colon cancer patients 
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remains controversial and deserves to be deeply investigated. In our cohort, we 
identified 44% of cases carrying a mutation in TP53 gene; in particular we found the 
vast majority of alterations in exons 5 and 7, where the most common hotspots take 
place. The most frequent identified mutations were the R175H (in exon 5), the G245S, 
R248Q, R248W (in exon 7) and the R306X (in exon 8). Percentage of alterations and 
types of mutations are in line with data on colorectal cancer. The correlation with the 
clinical outcome is now under evaluation. 
Finally, another marker, TS, was associated with the ability to identify patients who 
better benefit from 5FU administration. In fact, several studies demonstrated a better 
DFS and OS in patients characterized by low TS levels with respect to cases showing 
high percentage of TS (Kornmann M et al, 2002; Aguiar S Jr, 2005). We therefore planned to 
set up the investigation of this marker. However, we found several problems during 
methodologies development (e.g. no complete reproducibility of the analysis of the 
same specimens with different experiments), and the time we have spent to solve 
these problems was much longer than expected. The analyses are currently ongoing.  
 
In conclusion, looking at the whole cohort, we can confirm a better clinical outcome 
for adjuvant colon cancer patients treated with FOLFOX regimen with respect to 5FU 
treatment. MSI could be a useful tool indicating a better prognosis also for advanced 
colon cancer but its role in predicting 5FU or FOLFOX efficacy remains controversial. 
In addition, we propose to assess ERCC1 mRNA expression analysis before the 
administration of oxaliplatin-based chemotherapy, in order to early identify the 
patients who may benefit the most from this treatment. 
Finally, we suggest that KRAS mutational status could help clinicians in selecting the 
best chemotherapeutic treatment in the adjuvant setting: only KRAS mutant patients 
should be treated with a platinum-based chemotherapy, while patients whose 
tumour is KRAS wild-type could be treated with 5FU alone, thus preventing adverse 
side effect in a consistent number of cases. Our results, of course, deserve 
confirmations. 
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